Our medical imaging practice is led by Colin Miller, a recognized expert in medical imaging with over 25 years of experience pharmaceutical, device and biopharmaceutical services organizations. Much of his recent career was spent acting as a medical imaging consultant to biotech and pharma companies developing novel products. His consulting activities have spanned small molecules, biologics and medical devices and has supported several PMAs.

Examples of our recent work include:

Design and monitoring of anti-NGF imaging endpoints

The anti Nerve Growth Factor Inhibitors (anti-NGF) are a new class of powerful analgesics in clinical development.  They were put on clinical development hold by the FDA in 2012 due to joint related findings in patients.  The leader in the development of this class of compounds, Pfizer, approached Colin while at BioClinica to help develop a program to evaluate all the major articulating joints in all subjects entering the new Phase III program.  This was ground breaking work which included building a strong academic team and culminated in the publication of a new Imaging Atlas in 2015 which Colin helped co-author and the role out of the program.   With Colin joining Alacrita, Pfizer specifically requested Colin’s expertise to be maintained on the program and to continue the coordination of the radiology team and ensuring the imaging quality is at the level that is required to sustain the successful outcome of the program.

Radionucleotide M&A Strategy

Our client was looking to build a capability in radionucleotide imaging and was seeking merger and acquisition opportunities in Europe and the United States. One target company was developing a new Rubidium 82 radionuclide generator, which is used for cardiac imaging. Alacrita was commissioned to conduct technical, regulatory and commercial due diligence on the company. As part of the commercial due diligence, we interviewed 45 cardiologists across the United States and Europe, building a picture of the commercial attractiveness and reimbursement prospects of the product that was in development. Alacrita identified major flaws in the company’s execution plan and commercial projections, fundamentally undermining the business case for our client’s investment.

Rb82 Market Research

Our client was looking to build a capability in radionucleotide imaging and was seeking merger and acquisition opportunities in Europe and the United States. One target company was developing a new Rubidium 82 radionuclide generator, which is used for cardiac imaging. Alacrita was commissioned to conduct technical, regulatory and commercial due diligence on the company. As part of the commercial due diligence, we interviewed 45 cardiologists across the United States and Europe, building a picture of the commercial attractiveness and reimbursement prospects of the product that was in development. Alacrita identified major flaws in the company’s execution plan and commercial projections, fundamentally undermining the business case for our client’s investment.

Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn
Back

Stay in touch